Archives
-
Drug Repurposing for DNA Repair in CRISPR
2026-09-22
This study presents a large-scale screen of approved drugs to identify compounds that shift CRISPR-induced double-strand break repair toward NHEJ, MMEJ, or HDR. Its findings connect repair-outcome engineering with synthetic lethality and provide a framework for validating pathway modulators in genome editing, disease modeling, and cancer research.
-
Erastin and Ferroptosis: Assay Logic Beyond Viability
2026-09-22
Erastin is a ferroptosis inducer best used as a mechanistic perturbation rather than a standalone viability reagent. This guide connects redox biology, RAS/BRAF genotype, and necroptosis-aware assay design to improve interpretation in ferroptosis research.
-
SETD7, White Adipose Browning, and Metabolic Health
2026-09-21
The reference study identifies SETD7 as a negative regulator of inguinal white adipose tissue thermogenesis and links its depletion to an Adcy7–Sirt1–Creb1 signaling axis. Its mouse and adipocyte experiments suggest that selectively enhancing beige-fat function, rather than simply increasing adipogenesis, may improve energy expenditure and resistance to diet-induced metabolic dysfunction.
-
TSPAN18–STIM1 Signaling in Prostate Cancer Bone Metastasis
2026-09-21
Zhou et al. identify TSPAN18 as a regulator of STIM1 stability: by competing with TRIM32-mediated ubiquitination, TSPAN18 preserves STIM1, enhances store-operated calcium entry, and promotes prostate cancer bone metastasis. The study connects protein degradation control with the calcium signaling pathway and provides a mechanistic framework for evaluating TSPAN18 as a metastasis-related target.
-
Cortistatin, Akt, and Steroid-Induced ONFH
2026-09-20
The reference study identifies reduced cortistatin signaling as a feature of glucocorticoid-associated osteonecrosis of the femoral head and shows that cortistatin protects bone-forming and endothelial cells through GHSR1a/Akt. Its combination of patient samples, a rat model, and dexamethasone-treated cell systems provides a mechanistic framework linking oxidative-stress-related apoptosis, impaired osteogenesis, and vascular dysfunction.
-
Chicken GSDME Drives RNA Virus Pyroptosis
2026-09-19
The reference study identifies chicken GSDME as a principal pore-forming effector of RNA virus-induced pyroptosis, addressing a major gap created by the absence of GSDMD in chickens. Its combination of viral infection, Poly(I:C) stimulation, pathway analysis, and chGSDME loss-of-function experiments defines an MDA5–caspase-8/9–caspase-3/7–GSDME axis with implications for comparative virology and cell-death research.
-
Temafloxacin Activity Against Gram-Negative Bacteria
2026-09-18
Hardy’s overview synthesizes comparative in vitro evidence showing that temafloxacin was highly active against diverse respiratory, enteric, sexually transmitted, and other gram-negative pathogens, while remaining less active than ciprofloxacin against Pseudomonas aeruginosa. Its main contribution is a spectrum-wide interpretation of MIC data alongside pharmacokinetic considerations, helping researchers distinguish broad gram-negative coverage from organism-specific limitations.
-
Shh–Fgf Signaling in Species-Specific Penile Development
2026-09-18
A 2025 Cells study shows that species-specific penile morphogenesis is associated with differential Shh, Fgf10, and Fgfr2 expression in guinea pigs and mice. Combining comparative gene-expression analysis with genital-tubercle culture, the work links reduced Hedgehog and FGF activity to urethral groove formation and provides a framework for interpreting developmental signaling across mammalian models.
-
CGP 55845 hydrochloride for Reliable Assays
2026-09-17
This scenario-based guide explains how CGP 55845 hydrochloride, SKU B5086, can strengthen mechanistic controls in cell-based viability, proliferation, cytotoxicity, and neurotransmission workflows. It covers receptor selectivity, DMSO formulation, assay controls, interpretation against astrocytic GAT-3 biology, and practical vendor-selection criteria.
-
4-MUG Workflow for Lysosomal Assays
2026-09-17
4-Methylumbelliferyl-β-D-Glucopyranoside converts β-glucosidase and β-glucocerebrosidase activity into a sensitive fluorescent readout for kinetic, cell-based, and screening workflows. This practical guide connects 4-MUG assay design with optimized GBA1 mRNA research while emphasizing controls, pH-aware detection, and troubleshooting.
-
Belinostat (PXD101) HDAC Assay Guide
2026-09-16
Build reproducible HDAC inhibition, viability, cell-cycle, and chromatin assays with Belinostat (PXD101). This guide distinguishes validated bladder and prostate cancer use cases from exploratory applications linking HDAC activity to spliceosome regulation and PARP inhibitor sensitivity.
-
ICI 118,551 Hydrochloride in Neurovascular Assays
2026-09-15
ICI 118,551 hydrochloride is a selective β2-adrenoceptor antagonist used to dissect adrenergic signaling in mechanistic assays. This article connects its assay utility with emerging evidence on CKLF1-mediated neutrophil infiltration after ischemic stroke while clearly separating established findings from testable hypotheses.
-
Hesperadin and Mitotic Checkpoint Control
2026-09-15
Hesperadin is more than an Aurora B kinase inhibitor: it is a mechanistic probe for connecting chromosome behavior, histone H3 phosphorylation, cytokinesis, and checkpoint control. This translational perspective integrates Hesperadin with evidence on Plk1-regulated p31comet activity to guide assay design, target validation, and cancer research strategy.
-
LY364947 Workflows for TGF-β EMT Research
2026-09-14
LY364947 provides a receptor-proximal way to test TGF-β-driven Smad signaling, EMT, fibrosis, and tumor-cell plasticity. This guide translates the compound’s formulation requirements into practical assays and shows how the recent CDK4/6–BET study can sharpen pathway-resolved EMT experiments.
-
Hydroxycinnamic Acids, COPII, and cGAS-STING
2026-09-14
The reference study identifies the Sec24 B-site of the COPII coat complex as a molecular target of hydroxycinnamic acids, linking cargo sorting to STING trafficking and inflammation. Structural, cellular, and diabetic mouse data show that this mechanism can reduce TBK1/IRF3 activation, steatosis, and metabolic injury, while also offering a practical framework for studying trafficking-dependent inflammatory signaling.